Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants.

Terrero, Gretel; Datta, Jashodeep; Dennison, Jessica; Sussman, Daniel A; Lohse, Ines; Merchant, Nipun B; Hosein, Peter J · JAMA Oncol · 2022

case_series · Level IV

Where this comes from

Abstract

This case series describes ipilimumab/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency (HRD) pathogenic germline variants (PGVs).

Medical subject headings